NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $1.28 -0.03 (-2.29%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$1.32 +0.04 (+3.20%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Cardiff Oncology Stock (NASDAQ:CRDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$1.25▼$1.3250-Day Range$0.81▼$1.3752-Week Range$0.76▼$3.31Volume596,316 shsAverage Volume830,870 shsMarket Capitalization$99.57 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth. Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer. The company has also evaluated the therapy in other cancers, including metastatic pancreatic cancer and certain breast cancers. Onvansertib remains investigational and has not been approved for commercial use. The company was formerly known as Trovagene, Inc. and adopted the Cardiff Oncology name in 2019 as it shifted its focus toward oncology drug development. Based in San Diego, California, Cardiff Oncology conducts its clinical development activities primarily through collaborations and clinical sites in the United States. Mark Erlander, M.D., has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 44% of companies evaluated by MarketBeat, and ranked 426th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingCardiff Oncology has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialCardiff Oncology has a consensus price target of $7.50, representing about 485.9% upside from its current price of $1.28.Amount of Analyst CoverageCardiff Oncology has only been the subject of 3 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiff Oncology are expected to grow in the coming year, from ($0.60) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.35% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 12.06, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 5.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.57 News SentimentCardiff Oncology has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cardiff Oncology this week, compared to 3 articles on an average week.Search Interest6 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders8.80% of the stock of Cardiff Oncology is held by insiders.Percentage Held by Institutions16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDF Stock News HeadlinesBrokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $7.50September 23 at 3:16 AM | americanbankingnews.comCardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 25 at 1:00 AM | InvestorPlace (Ad)Analysts Issue Forecasts for CRDF Q3 EarningsSeptember 19, 2026 | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: High Tide (HITI), Cardiff Oncology (CRDF) and Benitec Biopharma (BNTC)September 17, 2026 | theglobeandmail.comHC Wainwright & Co. upgrades Cardiff Oncology to buy from neutralSeptember 16, 2026 | msn.comHC Wainwright Upgrades Cardiff Oncology to Buy From Neutral, Price Target is $9September 15, 2026 | marketscreener.comMCardiff Oncology Resolves Onvansertib Licensing Dispute With Nerviano; Shares RiseSeptember 15, 2026 | rttnews.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $2.81 on January 1st, 2026. Since then, CRDF stock has decreased by 54.4% and is now trading at $1.28. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.06 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 103.10% and a negative net margin of 7,885.43%. Who are Cardiff Oncology's major shareholders? Top institutional investors of Cardiff Oncology include BlackRock Inc. (1.42%), Flputnam Investment Management Co. (0.36%), Flputnam Investment Management Co. (0.32%) and X Square Capital LLC (0.30%). Insiders that own company stock include Gary W Pace and Mani Mohindru. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (12m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CRDF's financial health is in the Red zone, according to TradeSmith. CRDF has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees31Year Founded1999Price Target and Rating Average Price Target for Cardiff Oncology$7.50 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside+485.9%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.85 million Net Margins-7,885.43% Pretax Margin-7,884.06% Return on Equity-103.10% Return on Assets-75.52% Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.30 Sales & Book Value Annual Sales$590 thousand Price / Sales168.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book1.91Miscellaneous Outstanding Shares77,790,000Free Float70,949,000Market Cap$99.57 million OptionableOptionable Beta1.46 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CRDF) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
